Lincoln Pharmaceuticals Ltd
Pharmaceuticals & Biotechnology | Small Cap
Lincoln Pharmaceuticals demonstrates strong financial health, particularly in solvency and growth. The company efficiently manages its debts and shows good growth in revenue, operating profit, and assets. Profitability is also a notable strength, with solid returns on capital, equity, and assets, along with healthy margins. However, there are areas needing attention. The company's efficiency ratios are weak, indicating challenges in managing assets and inventory. Financial ratios also show some concerns, particularly regarding capital expenditures and earnings per share. While liquidity is reasonably managed, there is room for improvement. Overall, Lincoln Pharmaceuticals presents a mixed picture, with significant strengths offset by identifiable weaknesses in operational efficiency and financial management.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio3.60
- Profitability Ratio10.00
- Efficiency Ratio4.00
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio7.94
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBearish
- 4 HoursBearish
- 1 DayBearish
- 1 WeekBullish
- 1 MonthBullish
Lincoln Pharmaceuticals demonstrates strong financial health, particularly in solvency and growth. The company efficiently manages its debts and shows good growth in revenue, operating profit, and assets. Profitability is also a notable strength, with solid returns on capital, equity, and assets, along with healthy margins. However, there are areas needing attention. The company's efficiency ratios are weak, indicating challenges in managing assets and inventory. Financial ratios also show some concerns, particularly regarding capital expenditures and earnings per share. While liquidity is reasonably managed, there is room for improvement. Overall, Lincoln Pharmaceuticals presents a mixed picture, with significant strengths offset by identifiable weaknesses in operational efficiency and financial management.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
14.01
Industry Median
34.91
Small Cap Median
34.71
P/E RATIO
14.01
P/B RATIO
1.63
Industry Median
3.02
Small Cap Median
2.89
P/S RATIO
1.83
Industry Median
2.06
Small Cap Median
1.96
Others
PEG RATIO
0.00
EV/EBITDA RATIO
9.13
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹614.65 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤23rd Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
The company exhibits strong growth across various metrics, including revenue, operating profit, earnings per share, assets, and net income. This indicates a healthy expansion and effective management strategies. The consistent growth rates suggest the company is well-positioned for future success. Weighted average calculation method was used to arrive at the score.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 11.32 | 8.05 | 13.92 | 7.23 | 7.7 |
| Operating Profit Growth Rate | 10.34 | -6.25 | 11.11 | 2 | -3.92 |
| Earnings Per Share (EPS) Growth | 11.28 | 5.11 | 27.97 | -11.74 | 6.74 |
| Asset Growth Rate | 18.14 | 9.93 | 19.25 | 13.86 | 11.67 |
| Net Income Growth Rate | 11.29 | 5.8 | 27.4 | -11.83 | 7.32 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios reflect a mixed performance. While adjusted and cash earnings per share are at a lower level, book value per share is reasonable. Dividend per share distribution is also on the lower side, and capital expenditures suggest significant investments. This indicates potential areas needing attention to enhance overall financial performance. Weighted average calculation method was used to arrive at the score.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 34 | 36.5 | 46 | 40.5 | 44 |
| Cash Earnings Per Share (Cash EPS) | 38.5 | 41 | 52 | 47.5 | 51 |
| Book Value Per Share | 216.5 | 251 | 296.5 | 336 | 379 |
| Dividend Per Share (DPS) | 1.39 | 1.46 | 1.86 | 1.64 | 1.76 |
| Capital Expenditures (CapEx) | 46 | 13 | 40 | 19 | 24 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios reflect a strong performance. Healthy gross profit margin, return on capital employed, return on equity, return on assets, operating margin, and net margin indicate efficient operations and effective management. These metrics collectively suggest the company is well-positioned to generate profits and create value. Weighted average calculation method was used to arrive at the score.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.64 | 15.88 | 15.32 | 14.29 | 12.52 |
| Return on Capital Employed (ROCE) | 24 | 22 | 22 | 17 | 16 |
| Return on Equity (ROE) | 15.94 | 14.54 | 15.68 | 12.2 | 11.61 |
| Return on Assets (ROA) | 17.98 | 15.33 | 14.29 | 12.8 | 11.01 |
| Operating Margin | 20.34 | 17.65 | 17.21 | 16.37 | 14.61 |
| Net Margin | 14.62 | 14.31 | 16.01 | 13.16 | 13.11 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While inventory turnover is reasonable, fixed asset and capital turnover are relatively low, indicating underutilization of assets. Receivable days are high, suggesting challenges in collecting payments. Improving asset utilization and collection processes could enhance overall efficiency. Weighted average calculation method was used to arrive at the score.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.58 | 3.38 | 3.25 | 3.42 | 3.51 |
| Inventory Turnover Ratio | 6.4 | 6.01 | 6.68 | 6.86 | 7.38 |
| Receivables Turnover Ratio | 4.12 | 4.05 | 3.9 | 3.8 | 4.1 |
| Days Sales in Inventory Ratio | 57.03 | 60.73 | 54.64 | 53.21 | 49.46 |
| Receivable Days | 88.59 | 90.12 | 93.59 | 96.05 | 89.02 |
| Capital Turnover Ratio | 1.09 | 1.02 | 0.98 | 0.93 | 0.89 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company demonstrates excellent coverage ratios, with a high interest coverage ratio and a strong equity dividend coverage ratio. This indicates the company can comfortably meet its interest obligations and provides substantial dividend coverage for its shareholders. This showcases financial stability and shareholder-friendly policies. Weighted average calculation method was used to arrive at the score.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 97 | 51 | 123 | 55.5 | 117 |
| Equity Dividend Coverage Ratio | 25 | 25 | 25 | 25 | 25 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is exceptionally strong, with no debt relative to its equity or assets. This indicates a very conservative financial structure and a low risk of financial distress. While this provides stability, the company might be missing opportunities to leverage debt for growth or increased returns. Weighted average calculation method was used to arrive at the score.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0 | 0 |
| Debt to Equity Ratio | 0 | 0 | 0 | 0 | 0 |
| Equity Ratio | 1 | 1 | 1 | 1 | 1 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position reflects a mixed performance. While current and quick ratios indicate a good ability to meet short-term obligations, the cash ratio suggests a lower proportion of cash readily available. The operating cash flow ratio, being at an average level, implies the company generates a reasonable amount of cash from its operations to cover its current liabilities. Generally, the company appears to maintain sufficient liquidity, balancing its current assets and liabilities effectively. Weighted average calculation method was used to arrive at the score.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.87 | 3.99 | 3.54 | 3.5 | 3.67 |
| Quick Ratio | 2.15 | 3.16 | 2.82 | 2.86 | 3.07 |
| Cash Ratio | 0.19 | 0.4 | 0.13 | 0.18 | 0.25 |
| Operating Cash Flow Ratio | 0.75 | 0.46 | 0.59 | 0.74 | 0.8 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 3 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 5 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 8 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 9 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 13 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 14 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 15 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 16 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 17 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 18 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
Lincoln Pharmaceuticals' management demonstrates a mixed performance. The increasing promoter holding and strong ROCE reflect confidence and efficient capital utilization. However, declining profit growth and fluctuating OPM raise concerns. Consistent sales growth and prudent debt management are positives, but working capital management needs improvement, leading to a mixed overall assessment.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 49.78% | Increasing promoter confidence |
| Return on Capital Employed (ROCE) | 22.53% | Good Capital Utilization | |
| CONS | Compounded Profit Growth (TTM) | -11% | Declining Profit Growth |
| Operating Profit Margin (Latest Quarter) | 16% | Fluctuating Margins |
Financial Performance & Growth
Lincoln Pharmaceuticals' financial performance shows consistent sales growth but declining profit growth. Compounded profit growth has decreased, with the TTM figure at -11%. Quarterly results show fluctuating OPM %, and YOY Profit Growth % demonstrates volatility, ranging from -37.74% to 48.09% in the last five quarters. Profitability has not kept pace with sales, indicating challenges in maintaining margins and controlling costs.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Sales Growth (%) | 28.3% | 2.9% | 10.1% | 8.09% | 13.76% | 7.35% |
| Profit Growth (%) | 15.9% | 13.9% | 15.5% | 5.7% | 27.39% | -11% |
Capital Efficiency & Returns
Lincoln Pharmaceuticals demonstrates good capital efficiency with a strong Return on Capital Employed (ROCE) and Return on Equity (ROE). The ROCE stands at 22.53%, indicating effective utilization of capital. The ROE is 17.04%, suggesting good returns on shareholder funds. However, the Cash Conversion Cycle (CCC) has been fluctuating.
| Metric | Mar 2014 | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| ROCE % | 11% | 19% | 22% | 22% | 18% |
Financial Health & Prudence
Lincoln Pharmaceuticals exhibits excellent financial health and prudence. The company has significantly reduced its debt, with borrowings decreasing from ₹68 Cr in Mar 2014 to ₹0 Cr in Mar 2025. This indicates effective debt management.
| Metric | Mar 2014 | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Borrowings (Cr) | 68 | 64 | 5 | 2 | 0 |
Strategic & Operational Indicators
Lincoln Pharmaceuticals' strategic and operational indicators present a mixed picture. The company's working capital management shows inefficiencies, as indicated by fluctuating Debtor Days, Inventory Days, and Cash Conversion Cycle.
| Metric | Mar 2014 | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 154 | 92 | 96 | 98 | 97 |
| Inventory Days | 62 | 63 | 95 | 106 | 99 |
| Days Payable | 174 | 54 | 102 | 77 | 106 |
| Cash Conversion Cycle | 43 | 100 | 88 | 126 | 90 |
Lincoln Pharmaceuticals faces moderate risks. While the company exhibits strengths in debt management and promoter holding, potential risks include fluctuating profit margins and inefficiencies in working capital management. The decrease in compounded profit growth and volatility in quarterly profit growth indicate an increased financial risk.
Off-balance sheet exposure quantification
There is no off-balance sheet exposure identified in the provided data.
Contingent liability evaluation
There is no contingent liability evaluation identified in the provided data.
Accounting quality red flags
There are no accounting quality red flags identified in the provided data.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10615.26Bearish
- SMA 20619.54Bearish
- SMA 50630.84Bearish
- EMA 10616.27Bearish
- EMA 20620.16Bearish
- EMA 50627.14Bearish
- DEMA 10613.43Bullish
- DEMA 20612.97Bullish
- DEMA 50619.14Bearish
- TEMA 10615.00Bearish
- TEMA 20610.83Bullish
- TEMA 50618.36Bearish
- MACD-5.24Bullish
- ADX26.52Strong Trend
- IndicatorValueSignal
- RSI40.23Neutral
- CCI-35.43Neutral
- ROC 90.82Bullish
- ROC 14-3.43Bearish
- ROC 25-4.98Bearish
- Stoch K36.67Neutral
- Stoch D40.32Neutral
- IndicatorValueSignal
- BB Upper640.06Neutral
- BB Middle619.54Neutral
- BB Lower599.02Neutral
- ATR6.61Low Volatility
- IndicatorValueSignal
- MFI27.90Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10616.88Bearish
- SMA 20629.49Bearish
- SMA 50627.62Bearish
- EMA 10618.68Bearish
- EMA 20624.16Bearish
- EMA 50632.89Bearish
- DEMA 10611.99Bullish
- DEMA 20617.03Bearish
- DEMA 50619.65Bearish
- TEMA 10610.92Bullish
- TEMA 20612.94Bullish
- TEMA 50616.45Bearish
- MACD-6.02Bearish
- ADX21.02Weak Trend
- IndicatorValueSignal
- RSI40.89Neutral
- CCI-75.43Neutral
- ROC 9-2.62Bearish
- ROC 14-4.70Bearish
- ROC 25-2.58Bearish
- Stoch K24.37Neutral
- Stoch D25.84Neutral
- IndicatorValueSignal
- BB Upper659.01Neutral
- BB Middle629.48Neutral
- BB Lower599.96Neutral
- ATR9.77Low Volatility
- IndicatorValueSignal
- MFI33.96Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10629.51Bearish
- SMA 20630.48Bearish
- SMA 50656.16Bearish
- EMA 10623.94Bearish
- EMA 20630.04Bearish
- EMA 50641.31Bearish
- DEMA 10616.95Bearish
- DEMA 20619.09Bearish
- DEMA 50636.61Bearish
- TEMA 10613.15Bullish
- TEMA 20618.83Bearish
- TEMA 50N/AN/A
- MACD-8.06Bearish
- ADX16.87Weak Trend
- IndicatorValueSignal
- RSI41.37Neutral
- CCI-131.85Oversold
- ROC 9-3.35Bearish
- ROC 14-3.26Bearish
- ROC 253.54Bullish
- Stoch K21.18Neutral
- Stoch D19.61Oversold
- IndicatorValueSignal
- BB Upper653.53Neutral
- BB Middle630.48Neutral
- BB Lower607.44Neutral
- ATR16.67Low Volatility
- IndicatorValueSignal
- MFI44.00Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10631.96Bearish
- SMA 20652.45Bearish
- SMA 50640.83Bearish
- SMA 100602.99Bullish
- SMA 200559.99Bullish
- EMA 10633.16Bearish
- EMA 20641.52Bearish
- EMA 50636.53Bearish
- EMA 100611.25Bearish
- EMA 200589.00Bullish
- DEMA 10623.81Bearish
- DEMA 20632.13Bearish
- DEMA 50660.94Bearish
- DEMA 100652.83Bearish
- DEMA 200606.00Bullish
- TEMA 10624.32Bearish
- TEMA 20618.88Bearish
- TEMA 50651.37Bearish
- TEMA 100676.50Bearish
- TEMA 200637.46Bearish
- MACD-8.03Bearish
- ADX19.73Weak Trend
- IndicatorValueSignal
- RSI41.96Neutral
- CCI-63.58Neutral
- ROC 14-3.82Bearish
- ROC 25-8.60Bearish
- Stoch K34.78Neutral
- Stoch D34.53Neutral
- IndicatorValueSignal
- BB Upper757.10Neutral
- BB Middle652.45Neutral
- BB Lower547.80Neutral
- ATR30.65High Volatility
- IndicatorValueSignal
- MFI47.79Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20610.13Bullish
- SMA 50558.57Bullish
- EMA 20611.41Bullish
- EMA 50585.54Bullish
- DEMA 20650.11Bearish
- DEMA 50595.49Bullish
- TEMA 20669.15Bearish
- TEMA 50614.59Bullish
- MACD29.40Bullish
- ADX35.31Strong Trend
- IndicatorValueSignal
- RSI54.39Neutral
- CCI102.24Overbought
- ROC 143.14Bullish
- ROC 2531.53Bullish
- Stoch K38.46Neutral
- Stoch D53.46Neutral
- IndicatorValueSignal
- BB Upper731.19Neutral
- BB Middle610.13Neutral
- BB Lower489.07Neutral
- ATR65.08Low Volatility
- IndicatorValueSignal
- MFI74.86Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 6569.19Bullish
- SMA 12552.25Bullish
- SMA 24594.68Bullish
- EMA 6591.51Bullish
- EMA 12575.60Bullish
- EMA 24565.28Bullish
- DEMA 6621.62Bullish
- DEMA 12584.65Bullish
- DEMA 24597.87Bullish
- TEMA 6643.43Bearish
- TEMA 12598.60Bullish
- TEMA 24570.63Bullish
- MACD58.17Bearish
- ADX43.13Strong Trend
- IndicatorValueSignal
- RSI55.78Neutral
- CCI87.94Neutral
- ROC 254.69Bullish
- ROC 50103.78Bullish
- Stoch K16.94Oversold
- Stoch D34.45Neutral
- IndicatorValueSignal
- BB Upper741.38Neutral
- BB Middle581.23Neutral
- BB Lower421.07Neutral
- ATR110.26High Volatility
- IndicatorValueSignal
- MFI89.77Overbought